Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipromlimab and Tuvonralimab Combined With Chemotherapy as Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
NCT07374003Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2025
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pimivalimab and tuvonralimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Primary endpoint: Pathologic Complete Response Rate. Started Dec 2025; status: active, not recruiting.
02
Drugs
pimivalimabtuvonralimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07374003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374003.